217 related articles for article (PubMed ID: 25323007)
41. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
42. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
Hornberger JC; Best JH
Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
[TBL] [Abstract][Full Text] [Related]
43. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
Frei E; Visco C; Xu-Monette ZY; Dirnhofer S; Dybkær K; Orazi A; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Go RS; Piris MA; Møller MB; Young KH; Tzankov A
J Clin Pathol; 2013 Nov; 66(11):956-61. PubMed ID: 23775435
[TBL] [Abstract][Full Text] [Related]
44. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway.
Cordo Russo RI; García MG; Alaniz L; Blanco G; Alvarez E; Hajos SE
Int J Cancer; 2008 Mar; 122(5):1012-8. PubMed ID: 17985348
[TBL] [Abstract][Full Text] [Related]
45. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
[TBL] [Abstract][Full Text] [Related]
46. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features.
Wang WG; Cui WL; Wang L; Zhu F; Wan XC; Ping B; Zhou XY; Li XQ
Am J Surg Pathol; 2015 Jul; 39(7):902-11. PubMed ID: 25970684
[TBL] [Abstract][Full Text] [Related]
47. Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen.
Liu J; Quan L; Zhang C; Liu A; Tong D; Wang J
Oncol Lett; 2018 Mar; 15(3):3321-3328. PubMed ID: 29435074
[TBL] [Abstract][Full Text] [Related]
48. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma.
Wang WG; Liu ZB; Jiang XN; Lee J; Zhou XY; Li XQ
Histopathology; 2017 Nov; 71(5):778-785. PubMed ID: 28639315
[TBL] [Abstract][Full Text] [Related]
49. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
[TBL] [Abstract][Full Text] [Related]
50. PRDX6 promotes proliferation and induces chemo-resistance via peroxidase activity in Toledo diffuse large B-cell lymphoma cells.
Fang Z; Liu T; Liu X; Lu Y; Sun Y; Xiao R; Fan R; Liu L
Transl Cancer Res; 2019 Sep; 8(5):1772-1781. PubMed ID: 35116928
[TBL] [Abstract][Full Text] [Related]
51. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
[TBL] [Abstract][Full Text] [Related]
52. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1.
Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L
Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082
[TBL] [Abstract][Full Text] [Related]
53. Pyruvate dehydrogenase kinase 4-mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B-cell lymphoma by affecting the expression of MS4A1/CD20.
Jiang D; Mo Q; Sun X; Wang X; Dong M; Zhang G; Chen F; Zhao Q
Cancer Sci; 2021 Sep; 112(9):3585-3597. PubMed ID: 34252986
[TBL] [Abstract][Full Text] [Related]
54. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.
Wang J; Xu-Monette ZY; Jabbar KJ; Shen Q; Manyam GC; Tzankov A; Visco C; Wang J; Montes-Moreno S; Dybkær K; Tam W; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Wang S; Møller MB; Piris MA; Medeiros LJ; Li Y; Pham LV; Young KH
Am J Pathol; 2017 Aug; 187(8):1700-1716. PubMed ID: 28627414
[TBL] [Abstract][Full Text] [Related]
55. DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
Zhou N; Choi J; Grothusen G; Kim BJ; Ren D; Cao Z; Liu Y; Li Q; Inamdar A; Beer T; Tang HY; Perkey E; Maillard I; Bonasio R; Shi J; Ruella M; Wan L; Busino L
Blood; 2023 Sep; 142(11):973-988. PubMed ID: 37235754
[TBL] [Abstract][Full Text] [Related]
56. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway.
Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S
J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215
[TBL] [Abstract][Full Text] [Related]
57. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Li J; Qian C; Zhou Q; Li J; Li K; Yi P
Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
[TBL] [Abstract][Full Text] [Related]
58. AnnexinA5 promote glioma cell invasion and migration via the PI3K/Akt/NF-κB signaling pathway.
Ji C; Guo H; Zhang P; Kuang W; Fan Y; Wu L
J Neurooncol; 2018 Jul; 138(3):469-478. PubMed ID: 29520611
[TBL] [Abstract][Full Text] [Related]
59. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
[TBL] [Abstract][Full Text] [Related]
60. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
Fontan L; Goldstein R; Casalena G; Durant M; Teater MR; Wilson J; Phillip J; Xia M; Shah S; Us I; Shinglot H; Singh A; Inghirami G; Melnick A
Blood; 2021 Feb; 137(6):788-800. PubMed ID: 32785655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
